TEL-AML1 REAL TIME QUANTITATIVE PCR DETECTION KIT

ONKOTEST RQ2031-20



Product Information

The t(12;21)(p13;q22) translocation, which generates a TEL-AML1 (ETV6-RUNX1) chimeric gene, is the most common genetic lesion in pediatric acute lymphoblastic leukemia (ALL). It is observed in 22-27% of pediatric ALL and 3% of adult B-ALL patients; and is particularly associated with the early B-lineage ALL subtype. The most common breakpoint in the TEL gene resides in exon 5 which fuses to the 2nd exon of the AML-1 gene. Rarely a fusion between TEL exon 5 and AML-1 exon 3 is also observed. It is important to perform molecular diagnostic screening for the presence of t(12;21), along with t(9;22), t(4;11)and t(1;19) in pediatric ALL to determine prognosis and therapeutic approaches. The kit is designed to detect the presence of exon5TEL/exon2AML1 and exon5TEL/exon3AML1 fusion mRNA's. This kit will not detect mRNA breakpoint products that are outside the sequence confined by the PCR primers provided within the kit.

Figure 1: Annealing locations of the PCR primers and hydrolysis probe




Figure 1: Annealing locations of the PCR primers and hydrolysis probe

Figure 1: Annealing locations of the PCR primers and hydrolysis probe

The Onkotest RQ2031-20 kit allow to detect quantification of TEL-AML1 copy number by real-time quantitative PCR (gPCR) technique. The Onkotest RQ2031-20 kit uses fluorescent labeled probe and PCR primers to detect the TEL-AML1 encoding the chimeric gene product mRNA with high sensitivity. The main working principle is to use known amounts of TEL-AML1 and ABL (internal control gene) calibrators to generate a standard curve from which sample TEL-AML1 mRNA can be quantified relative to control ABL gene expression. cDNA converted from total RNA of patient's bone marrow/blood samples are used as template in the reactions (reagents for cDNA conversion are not provided with the kit). Sample cDNA quality is checked by using a probe and PCR primers of an internal control gene (ABL), provided with the kit. The Onkotest RQ2031-20 kit will only detect TEL-AML1 mRNA that is specific for the primers used; it kit will not detect other mRNA breakpoint products that are outside the sequence confined by the PCR primers provided within the kit. The Onkotest RQ2031-20 kit is designed to work with all real time thermal cycler instruments.

Kit Contents

Tube No:	Labeling&Contents	Volume
1	TEL-AML1 Primer Mix	110 µl
2	TEL-AML1 Probe	110 µl
3	ABL Primer Mix	90 µl
4	ABL Probe	90 µl
5	PCR-Grade dH ₂ O	500 µl
	Content-Calibrators	Volume
	ABL 10e2	50 µl
	ABL 10e3	50 µl
	ABL 10e4	50 µl
	ABL 10e5	50 µl
	TEL-AML1 10e1	50 µl
	TEL-AML1 10e2	50 µl
	TEL-AML1 10e3	50 µl
	TEL-AML1 10e4	50 µl
	TEL-AML1 10e5	50 µl
	TEL-AML1 10e6	50 µl

• All reagents are ready to use

Kit Description

The **Onkotest RQ2031-20** kit uses cDNA of patients (converted from total RNA by reverse transcription) as template for PCR reactions. Real time PCR will amplify the target TEL-AML1 and ABL regions by using highly specific primers provided within the kit. The hydrolysis probe will specifically hybridize to its own complementary target sequence within the amplified PCR product.

It is a dual labeled probe in which the fluorophore FAM (6carboxyfluorescein) is covalently attached to the 5'-end; while a quencher, BHQ (Black hole quencher) is attached at the 3'-end. The quencher molecule quenches the fluorescence emitted by the fluorophore, so as long as the fluorophore and the guencher are in proximity, fluorescence signals are inhibited. When the probe hybridizes to its specific sequence, the $5' \rightarrow 3'$ exonuclease activity of the polymerase degrades the probe and breaks the close proximity between the fluorophore and the quencher. As a result the fluorophore is relieved of the quenching effect and is able to emit fluorescence which can be detected (Figure 2). The fluorescence detected is directly proportional to the amount of fluorophore released, therefore also directly proportional to the amount of DNA template present in the PCR. The hydrolysis probe is both highly sensitive and highly specific; for it requires the presence and amplification of its complementary sequence by the specific primers provided within Onkotest RQ2031-20 kit.




Figure 2: Hydrolysis probe

The positive and internal controls provided with the kit are aimed to prevent false negative results that may be the outcome of failed reactions or poor template quality. Using H_2O as a negative control aims to prevent false positive results by the detection of cross contamination

Sample Material

The **Onkotest RQ2031-20** kit is optimized for the accurate detection of TEL-AML1 transcripts in bone marrow and/or peripheral blood samples of patients. The kit uses cDNA (converted from total RNA by reverse transcription) as template for the PCR reactions. Using patient RNA directly as template will not yield results.

*EDTA-ethylenediaminetetraacetic acid is preferred as anticoagulant, heparin may inhibit PCR reactions.

IMPORTANT: To minimize cross contamination risks, the calibrator tubes inside the kit should be stored separately from test samples and added to the reaction mix in a separate area during assay preparation.

Number of Tests

The **Onkotest RQ2031-20** kit contains primers and probes for TEL-AML1 and internal control ABL reactions, enough for duplicate analyses of 20 patient samples. Calibrators and patient samples should be work as duplicate.

Handling & Storage

The components of kit should be stored at -20°C. Protect fluorescent probes (tubes 2 and 4) from light. While setting up PCR reactions, kit components should be placed on ice. Maximum of freeze-thaw cycles:5

Materials Required But Not Provided

Equipment

Real-time thermal cycler Laminar flow hood/biological safety cabinet Vortex Spin-down microcentrifuge Micropipettes *Consumables* Real Time PCR master mix cDNA conversion kit Sterile filtered pipette tips Serological pipettes 0,2 ml PCR tubes/Capillary tubes/strip tubes/plates (depending on real-time instrument)

Important Notes & Precautions:

- Separate areas dedicated for RNA isolation, cDNA/PCR reaction preparation and agarose gel electrophoresis is strongly recommended.
- Lab coats and safety equipment (goggles ect.) should be specifically designated to each area
- Separate micropipette sets for each area is strongly recommended.
- Micropipette tips should be DNAse-RNAse free and preferably filtered.
- To prevent cross contamination between patient samples, total RNA isolation of samples should be performed separately.
- Avoid biohazard exposure by observing universal precautions when handling all biological materials.
- Minimize cross contamination by storing calibrator tubes separately from test samples and add to the reaction mix in a separate area during assay preparation.
- Avoid direct contact of reagents. In case of direct contact, wash thoroughly with water. Seek medical care in case of inhalation and/or swallowing.
- Do not use reagents with different lot numbers in sample reactions.

Before You Begin

Before starting, be sure the tube contents are fully dissolved. Mix tube contents briefly by vortexing, followed by a spin-down centrifugation to bring down tube contents. Keep all test samples and kit contents on ice when in use.

Procedure

Negative control (NC) - **(dH2O)**: The "no template negative control". This control replaces template cDNA with water in the PCR reactions. It aims for the detection of any cross contamination (false positive results). The negative control should not give any positive signal. In cases where a positive reaction signal is detected, all reactions must be repeated.

Patient sample internal control (IC-ABL): The ABL gene product is used as internal control. cDNA from patient samples are used as template for this reaction. The PCR product size is 123 bp. It aims for the detection of poor sample quality (false negative results). Patient sample PCRs that are negative for ABL, designate poor template quality (RNA and/or cDNA unsuitable for analyses). In case of a negative internal control (negative result for ABL expression), a new cDNA conversion from total RNA should be performed and both TEL-AML1 and ABL PCR reactions should be repeated. New RNA extraction from patient bone marrow/peripheral blood should be performed in cases where a second negative result for the internal control is obtained.

Preparation of the Real-time PCR Mix

PCR Reaction Panel for One Patient *

	Negative Control (ABL)*	Calibrator (ABL)	Negative Control (TEL-AML1)*	Calibrator (TEL-AML1)	Patient ABL	Patient TEL-AML1
ddH2O (tube 5)	to 20μl	to 20μl	to 20μl	to 20μl	to 20µl	to 20μl
Real -time master mix (not provided)	1X	1X	1X	1X	1X	1X
TEL-AML1 primer mix (tube 1)	-	-	1 µl	1 µl	-	1 µl
TEL-AML1 probe (tube 2)	-	-	1 µl	1 µl	-	1 µl
Calibrators (ABL/TEL-AML1)	-	5 µl	-	5 µl	-	-
ABL primer (tube 3)	1 μΙ	1 μΙ	-	-	1 μΙ	-
ABL probe (tube 4)	1 μΙ	1 μΙ	-	-	1μΙ	-
Patient cDNA sample	-	-	-	-	5 µl	5 µl

Total reaction volume 20 μL

* Negative Control: ddH₂O used instead of template

Thermal Profile for Real-Time PCR Instrument

Use the following profile on your real-time PCR instrument. When creating your thermal profile if your instrument requires you to define parameters for the 5' and 3' ends: select 6-FAM for the 5 prime end, and "quencher dye" for the 3 prime end.

Denaturation	95°C	10 minutes	1 cycle
Reaction	95°C	10 seconds	
	58°C	40 seconds (signal accumulation occurs)	45 cycles
Cooling	40 °C	1 minute	1 cycle

Analyses

The instrument you use will evaluate the real-time PCR reactions using its own software by generating standard curves for both TEL-AML1 and ABL; from which relative amounts of the genes can be calculated in both control and test samples. By dividing the TEL-AML1 value with the ABL value we obtain the TEL-AML1/ABL.

Evaluation of Results

We recommend reporting patient TEL-AML1 copy number by the following calculation:

Normalized TEL-AML1 copy number= TEL-AML1 /ABL

Kit Capacity	20 samples duplicate		
Control Gene	ABL		
Reported Values	TEL-AML1 Transcript		
Components	TEL-AML1 primer mix/probe		
	ABL primer mix /probe		
	DNA Plasmid Control (TEL-AML1)		
Tested Platforms	Roche [®] LC480, LightCycler [®] 1.5, 2.0;		
	ABI [®] StepOnePlus [™] ; Corbett [®] Rotor-		
	Gene [®] 6000 and Rotor-Gene Q		
Product Order No.	RQ2031-20		

Product Specifications

CONTACT:



ONKO TEST GENETİK ARAŞTIRMA PROJELENDİRME SANAYİ VE TİCARET LTD.ŞTİ.

Dokuz Eylul University DEPARK -(Technology Development Zone) Office: 202 Balcova, İZMİR-TURKEY Tel: 90-232-4642088 90-216-5732591 info@onkotest.com

The following symbols may appear on the packaging and labeling:

((CE sign
	Manufacturer
i	Consult instructions for use
IVD	In vitro diagnostic
	Manufacturing date
REF	Catalog number
LOT	Lot number
-18°C	Temperature limitation
X	Expiration date
	((

кк2031-20/01.03.2016/00 С С